Article

Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma

Zhejiang University of Technology, Chaowang Road, Hangzhou, 310014, People's Republic of China
Biomedical Chromatography (Impact Factor: 1.95). 01/2013; 27(1). DOI: 10.1002/bmc.2744
Source: PubMed

ABSTRACT A rapid and sensitive analytical method based on liquid chromatography coupled to tandem mass spectrometry detection with positive ion electrospray ionization was developed for the determination of febuxostat in human plasma using d(7) -febuxostat as the internal standard (IS). A simple protein precipitation was performed using acetonitrile. The analyte and IS were subjected to chromatographic analysis on a Capcell PAK C(18) column (4.6 × 100 mm, 5 µm) using acetonitrile-5 mm ammonium acetate-formic acid (85:15:0.015, v/v/v) as the mobile phase at a flow rate of 0.6 mL/min. An Agilent 6460 electrospray tandem mass spectrometer was operated in the multiple reaction monitoring mode. The precursor-to-product ion transitions m/z 317 → m/z 261 (febuxsotat) and m/z 324 → m/z (261 + 262) (d(7) -febuxostat, IS) were used for quantitation. The results were linear over the studied range (10.0-5000 ng/mL), and the total analysis time for each chromatograph was 3 min. The intra- and inter-day precisions were less than 7.9 and 7.2%, respectively, and the accuracy was within ±4.2%. No evidence of analyte instability in human plasma was observed storage at -20°C for 31 days. This method was successfully applied in the determination of febuxostat concentrations in plasma samples from healthy Chinese volunteers. Copyright © 2012 John Wiley & Sons, Ltd.

0 Bookmarks
 · 
171 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A stability-indicating micellar electrokinetic capillary chromatography (MEKC) method was validated for the analysis of febuxostat in pharmaceutical formulations, using lisinopril as the internal standard (IS). A fused-silica capillary (50 μm i.d.; effective length, 40 cm) was maintained at 30 °C, and the applied voltage was 20 kV. The background electrolyte solution consisted of 15 mmol L−1 sodium tetraborate buffer and 25 mmol L−1 sodium dodecyl sulphate solution at pH 10. Injections were performed using a pressure mode at 50 mbar for 45 s, with detection using a photodiode array detector set at 216 nm. Specificity and stability-indicating capability were established in degradation studies, which also showed that there was no interference of the excipients. The method was linear over the concentration range of 0.10-50 μg mL−1 (r2 = 0.9993) and the limit of detection (LOD) and limit of quantitation (LOQ) were 0.05 μg mL−1 and 0.10 μg mL−1, respectively. The accuracy was 99.89% with a relative error lower than 1.04%. The proposed method was applied to the quantitative analysis of febuxostat in tablet dosage forms and in human plasma, and the results were correlated with those of a validated reversed-phase (RP-LC) method, in attempts to improve quality control of pharmaceutical products.
    Analytical methods 06/2014; 6(11):3811. DOI:10.1039/c4ay00145a · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Due to wide consumption of flavonoids in the dietary supplement, and an imperative role of CYPs and P-glycoprotein inhibition in drug disposition. So there is increasing scientific interest in drug-flavonoid interactions. Objective: The present study aims to investigate the effect of morin, a flavonoid, on the pharmacokinetics of febuxostat in rats. Methods: A simple ultra-performance liquid chromatography method has been developed for the calculation of febuxostat in 100 µl rat plasma using febuxostat D7 as an internal standard (IS). The assay procedure involved a single-step, liquid-liquid extraction of febuxostat and IS from plasma with methanol. Pharmacokinetic parameters of febuxostat were determined in rats after an oral administration of febuxostat (5 mg/kg) to rats in the control, coadministered and pretreated groups of morin (10 mg/kg). Results: Compared to the control rats given febuxostat alone, the Cmax and AUC of febuxostat increased by 18 - 20 and 47 - 50%, respectively, in rats pretreated with morin. The plasma half-life (t1/2) of the pretreated group is increased by 2.5-fold compared with the control group. Consequently, relative bioavailability values of febuxostat in the rats pretreated with morin were significantly higher (p < 0.05) than those from the control and coadministered groups. Increased bioavailability indicates that the presence of morin could be effective in inhibiting CYP1A1, CYP1A2 and CYP3A4-mediated metabolism and/or effective in inhibiting P-glycoprotein-mediated cellular efflux of febuxostat. Conclusion: The presence of morin significantly enhanced the oral exposure of febuxostat, suggesting that concurrent use of morin or morin-containing dietary supplements with febuxostat should be verified to avoid drug-flavonoid interactions.
    Expert Opinion on Drug Metabolism &amp Toxicology 02/2014; DOI:10.1517/17425255.2014.885017 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An HPLC-MS/MS method for simultaneously determination of the active metabolites (67M-1, 67M-2 and 67M-4) in human plasma using clopidogrel as the internal standard was developed and validated. The compounds were extracted by protein precipitation using acetonitrile and separated using a C8 column by a gradient elution with the mobile phase consisting of acetonitrile (containing 0.1% formic acid) and 0.1% formic acid. Quantification was performed using multiple reaction monitoring in positive mode with m/z transitions of 333.1-261.0, 333.1-261.0, 347.0-261.0 and 322.2-184.1 for 67M-1, 67M-2, 67M-4 and clopidogrel (Internal Standard), respectively. This method was validated in terms of specificity, linearity, precision, accuracy, and stability. The lower limit of quantification of this method was 0.5ng/mL and the calibration curve was linear over the concentration range of 0.5-150ng/mL. The intra- and inter-run precision was less than 11.67% and 8.64%, respectively, with the accuracy between 98.33% and 108.38%. The samples were stable under all the tested conditions. This method has been successfully applied to the pharmacokinetic study of febuxostat in healthy Chinese volunteers following oral administration of 40mg and 80mg febuxostat.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 09/2014; 970C:24-30. DOI:10.1016/j.jchromb.2014.08.038 · 2.78 Impact Factor